Ovarian cancer HRQoL ‘not compromised’ with trebananib

Treatment with the antiangiogenesis inhibitor trebananib does not adversely affect health-related quality of life in patients with recurrent ovarian cancer, suggests the placebo-controlled TRINOVA-1 trial.
Source: MedWire News - Category: Consumer Health News Tags: Oncology Source Type: news